India, Sept. 1 -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK, RHHBY,2096.HK, RHHBY,RO.SW,2096.HK, RHHBY,RO.SW,ROG.SW, SMHGF, SMHGF,ROG.SW, SMHGF) announced it has entered into an exclusive global licensing agreement with Roche (2096.HK, RHHBY,RO.SW,ROG.SW, SMHGF) for the development and commercialization of SIM0660.
SIM0660 is a tri-specific antibody targeting CD79a, CD19, and CD3. The therapy is designed to address B-cell-mediated diseases, including certain cancers and autoimmune conditions.
Under the terms of the agreement, Roche will acquire exclusive worldwide rights to develop, manufacture, and commercialize SIM0660. Simcere Zaiming is eligible to receive up to $1.53 billion in total payments, including $...